Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$5.15 USD
-0.15 (-2.83%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $5.15 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 121 - 140 ( 221 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Solid Method to the Madness. Maintaining Buy, $17 PT.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SY-1425 Early Data in Unfit, Biomarker-positive AML Patients
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syros Abandons Drug Candidate But Stays Committed to CDK7 Targeting
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Data and Clarity on the Regulatory Front
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Timeline Remains Steady for a Data Rich 2H19 and 2020. Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SYRS gets Serious with Several Pipeline Updates Through H1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Assuming at Buy $17 PT. Here''s How We''re Looking at Syros.
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage, placing shares Under Review, and removing our price target and estimates
Provider: Roth Capital Partners, Inc.
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.